Skip to main content

alpha-Synuclein [p Ser129] Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-61121

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-61121
NBP2-61121-0.025ml

Key Product Details

Validated by

Biological Validation

Species Reactivity

Human, Mouse, Rat

Applications

ELISA, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Concentration

0.5 mg/ml

Product Specifications

Immunogen

This alpha-Synuclein [p Ser129] Antibody was developed against Synthetic peptide of human alpha-Synuclein pSer129 (40-140 aa), conjugated to Keyhole Limpet Hemocyanin (KLH).

Modification

p Ser129

Specificity

This alpha-Synuclein [p Ser129] Antibody is specific for phosphorylated serine 129 on alpha-synuclein. Does not detect unphosphorylated serine 129 alpha-synuclein. Detects bands at 100, 75, 45, 15 kDa. Bands above 15 kDa are oligomers.

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for alpha-Synuclein [p Ser129] Antibody

Western Blot: alpha-Synuclein [p Ser129] Antibody [NBP2-61121]

Western Blot: alpha-Synuclein [p Ser129] Antibody [NBP2-61121]

Western Blot: alpha-Synuclein [p Ser129] Antibody [NBP2-61121] - Western blot analysis of Human, Mouse brain lysate showing detection of ~16 kDa alpha-Synuclein protein using Rabbit Anti-alpha-Synuclein Polyclonal Antibody (NBP2-61121). Lane 1: Molecular Weight Ladder (MW). Lane 2: Human brain lysate. Lane 3: Mouse brain lysate. Lane 4: Alpha Synuclein Monomer (0.5 ug). Load: 15 ug. Block: 2.5% BSA in TBST. Primary Antibody: Rabbit Anti-alpha-Synuclein Polyclonal Antibody (NBP2-61121) at 1:1000 for 2 hours at RT. Secondary Antibody: Goat Anti-Rabbit HRP:IgG at 1:3000 for 1 hour at RT. Color Development: ECL solution for 5 min at RT. Predicted/Observed Size: ~16 kDa. Other Band(s): 100, 75, 45, 30,16 kDa.
Immunocytochemistry/ Immunofluorescence: alpha-Synuclein [p Ser129] Antibody [NBP2-61121]

Immunocytochemistry/ Immunofluorescence: alpha-Synuclein [p Ser129] Antibody [NBP2-61121]

Immunocytochemistry/Immunofluorescence: alpha-Synuclein [p Ser129] Antibody [NBP2-61121] - Phospho serine 129 antibody (NBP2-61121) was used to detect phosphorylated alpha synuclein in primary mouse hippocampal neurons treated with 100 nM sonicated mouse alpha synuclein PFFs (A). Phosphorylated alpha synuclein was visible in perinucleus and neurites compared to untreated control (B). Read the protocol at pabmabs.com/?p=7901. Image courtesy of Trine Rasmussen, Simon Molgaard Jensen at Aarhus University.
Immunohistochemistry: alpha-Synuclein [p Ser129] Antibody [NBP2-61121]

Immunohistochemistry: alpha-Synuclein [p Ser129] Antibody [NBP2-61121]

Immunohistochemistry: alpha-Synuclein [p Ser129] Antibody [NBP2-61121] - Immunohistochemistry analysis using Rabbit Anti-alpha-Synuclein Polyclonal Antibody (NBP2-61121). Tissue: Brain. Species: Human. Fixation: Formalin Fixed Paraffin-Embedded. Primary Antibody: Rabbit Anti-alpha-Synuclein Polyclonal Antibody (NBP2-61121) at 1:50 for 30 min at RT. Counterstain: Hematoxylin. Magnification: 10X. HRP-DAB Detection.

Applications for alpha-Synuclein [p Ser129] Antibody

Application
Recommended Usage

Immunohistochemistry

1:500

Immunohistochemistry-Paraffin

1:500

Western Blot

1:1000
Application Notes
A 1:1000 dilution of this Antibody was sufficient for detection of Alpha Synuclein pSer129 in 15 ug of human brain cell lysates by ECL immunoblot analysis using goat anti-rabbit IgG:HRP as the secondary antibody.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Peptide affinity purified

Formulation

PBS (pH 7.4), 50% Glycerol

Preservative

0.09% Sodium Azide

Concentration

0.5 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C short term. Aliquot and store at -80C long term. Avoid freeze-thaw cycles.

Background: alpha-Synuclein

Alpha-synuclein, a member of the synuclein family, is a protein that was first identified in 1988 whose name is derived from its localization to both the synapse and nucleus (1-3). Specifically, it is expressed primarily in the brain, including Lewy Bodies (1-6). Alpha-synuclein is encoded by the SNCA gene, located on chromosome 4p21, and is processed as a 140 amino acid (aa) protein with a theoretical molecular weight of 14 kDa (1,2,4). Structurally alpha-synuclein consists of a N-terminal binding domain (1-60 aa), a central domain core region called the non-amyloid-beta component (NAC) (61-95 aa), and a C-terminal domain (96-140 aa) (1-3). The N-terminal region contains aa repeats with a KTKEGV consensus sequence that gives the protein its alpha-helical structure that associates with lipid membranes (1-4). The hydrophobic NAC region is responsible for alpha-synuclein aggregation and fibril formation (1-4). The acidic C-terminal tail is largely unstructured but can be targeted for post-translational modifications (1-4). The function of alpha-synuclein is not entirely understood, but it is shown to have a role in suppression of apoptosis, acting as a molecular chaperone, regulating glucose, and modulating calmodulin activity (1,3).

A number of studies have revealed that alpha-synuclein aggregation is a hallmark feature in a number of neurodegenerative diseases, referred to as synucleinopathies (2-4). Alpha-synuclein protein aggregates are a large component of Lewy bodies that are present in Parkinson's disease (PD), Lewy body dementia (LBD), and multiple system atrophy (1-6). Research has shown phosphorylation of alpha-synuclein at Ser129 moves the protein from the nucleus to the cytoplasm and promotes fibril formation associated with synucleinopathies (1,2,5). Recent studies also suggest that alpha-synuclein accumulation can prevent mitochondrial import machinery causing mitochondrial dysfunction that is often observed in neurodegeneration (5). It is thought that preventing alpha-synuclein aggregation may prevent PD, thus alpha-synuclein is a target for many potential therapeutic interventions aimed at decreasing aggregate formation or increasing clearance (1,2,4-6).

References

1. Villar-Pique, A., Lopes da Fonseca, T., & Outeiro, T. F. (2016). Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. Journal of neurochemistry. https://doi.org/10.1111/jnc.13249

2. Emamzadeh F. N. (2016). Alpha-synuclein structure, functions, and interactions. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. https://doi.org/10.4103/1735-1995.181989

3. Burre J. (2015). The Synaptic Function of alpha-Synuclein. Journal of Parkinson's disease. https://doi.org/10.3233/JPD-150642

4. Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E. (2013). The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nature reviews. Neuroscience. https://doi.org/10.1038/nrn3406

5. Rocha, E. M., De Miranda, B., & Sanders, L. H. (2018). Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. Neurobiology of disease. https://doi.org/10.1016/j.nbd.2017.04.004

6. O'Leary, E. I., & Lee, J. C. (2019). Interplay between alpha-synuclein amyloid formation and membrane structure. Biochimica et biophysica acta. Proteins and proteomics. https://doi.org/10.1016/j.bbapap.2018.09.012

Alternate Names

NACP, PARK1, PARK4, SNCA, Synuclein-alpha

Gene Symbol

SNCA

Additional alpha-Synuclein Products

Product Documents for alpha-Synuclein [p Ser129] Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for alpha-Synuclein [p Ser129] Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...